42
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Prescription of non-steroidal anti-inflammatory drugs for patients with inflammatory arthritis decreases with the initiation of tumour necrosis factor inhibitor therapy: results from the ICEBIO registry

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Received 05 Jan 2024, Accepted 06 May 2024, Published online: 04 Jun 2024

References

  • Olivieri I, D’Angelo S, Palazzi C, Padula A. Advances in the management of psoriatic arthritis. Nat Rev Rheumatol 2014;10:531–42.
  • Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis. JAMA 2018;320:1360.
  • Einarsson JT, Geborek P, Saxne T, Kristensen LE, Meliha C, Einarsson JT, et al. Sustained remission improves physical function in patients with established rheumatoid arthritis, and should be a treatment goal: a prospective observational cohort study from Southern Sweden. J Rheumatol 2016;43:1017–23.
  • Lampa J. Pain without inflammation in rheumatic diseases. Best Pract Res Clin Rheumatol 2019;33:101439.
  • Olofsson T, Wallman JK, Jöud A, Schelin ME, Ernestam S, van Vollenhoven R, et al. Pain over 2 years after start of biological versus conventional combination treatment in early rheumatoid arthritis: results from the randomised controlled SWEFOT trial. Arthritis Care Res (Hoboken) 2021;73:1312–21.
  • van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017;76:978–91.
  • Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960–77.
  • Gossec L, Baraliakos X, Kerschbaumer A, De Wit M, McInnes I, Dougados M, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 2020;79:S700–12.
  • Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 2022;18:465–79.
  • Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci 2013;16:821–47.
  • Hojgaard P, Glintborg B, Kristensen LE, Gudbjornsson B, Love TJ, Dreyer L. The influence of obesity on response to tumour necrosis factor-alpha inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. Rheumatology (Oxford) 2016;55:2191–9.
  • Glintborg B, Gudbjornsson B, Krogh NS, Omerovic E, Manilo N, Holland-Fischer M, et al. Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO. Rheumatology (Oxford) 2014;53:2100–9.
  • Hetland ML. DANBIO: a nationwide registry of biological therapies in Denmark. Clin Exp Rheumatol 2005;23:S205–7.
  • Hagstofan [Internet]. [cited 2024 May 24]. Available from: http://www.hagstofa.is.
  • WHOCC - Definition and general considerations [Internet]. [cited 2024 May 24]. Available from: https://www.whocc.no/ddd/definition_and_general_considera/.
  • Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther 2013;15:S2.
  • Moltó A, Granger B, Wendling D, Breban M, Dougados M, Gossec L. Brief report: nonsteroidal antiinflammatory drug-sparing effect of tumor necrosis factor inhibitors in early axial spondyloarthritis: results from the DESIR cohort. Arthritis Rheumatol 2015;67:2363–8.
  • Dougados M, Wood E, Combe B, Schaeverbeke T, Miceli-Richard C, Berenbaum F, et al. Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study. Arthritis Res Ther 2014;16:481.
  • Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, Andersson C, Folke F, Nielsen MB, et al. Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among myocardial infarction patients – a nationwide study. PLOS ONE 2013;8:e54309.
  • Arfè A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ 2016;354:i4857.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.